BUFFALO, N.Y., Sept. 15 /PRNewswire/ -- Kinex Pharmaceuticals announced that David Hsia, Ph.D. has been appointed to the Company's Board of Directors.
Dr. Hsia is a pharmaceutical veteran. He is a co-founder of Watson Pharmaceuticals, a publicly traded company listed in New York Stock Exchange (ticker: WPI). He was formerly Senior Vice President, Scientific Affairs of Watson Pharmaceuticals before his retirement. He has been involved in the development of various pharmaceutical formulations for over twenty years. Dr. Hsia received a Ph.D. in Industrial and Physical Pharmacy from Purdue University in 1975.
"Dr. Hsia is well known for his expertise in pharmaceutical development in our industry," commented Dr. Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "As the Company moves forward, we look forward to leveraging the full breadth of David's expertise as a Board member to assist us in developing our new drug candidates," Commented Dr. Johnson Lau, Executive Chairman of the Board.
"I am delighted to have a chance to work with the team at Kinex. The company's pipeline is very strong and I am glad to have this opportunity to assist to further advance their product pipeline," commented Dr. Hsia.
About Kinex Pharmaceuticals
Kinex is a drug discovery and development company that is focused on the use of its platform technology and compound libraries to identify and develop peptide-competitive kinase inhibitors. The Company's clinical compound KX2-391 is a selective Src kinase inhibitor that is currently in Phase 1 trials for oncology. Kinex's pipeline is focused on selective inhibitors for kinase targets that are important in oncology and inflammation and immunology. The Company is located in the New York State Center of Excellence in Bioinformatics and Life Sciences, on the Buffalo Niagara Medical Campus in Buffalo, New York.
|SOURCE Kinex Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved